Target intelligence / Profile preview

Prebiotic oligosaccharide (None)

Target
None
Molecular classification
Other (specifically: Non-digestible carbohydrate/polymer), Not classified as receptor, enzyme, transporter, etc., Dietary fiber, Functional food ingredient, Complex carbohydrate
01

Overview

Prebiotic oligosaccharides are a class of short-chain, non-digestible carbohydrates (3–10 monosaccharide units), naturally occurring in many plants and foods, or produced industrially, defined by their ability to selectively promote the growth and metabolic activity of beneficial gut and skin microbiota, resulting in various health benefits. They are not themselves classical drug targets, but act as functional dietary ingredients or supplements. Different types, such as fructo-oligosaccharides, galacto-oligosaccharides, and others, have distinct structures and sources. Biological effects are mediated by fermentation in the colon, leading to the formation of short-chain fatty acids, improvements in barrier function, immunomodulation, and influences on inflammatory and immune-mediated diseases, including roles in both gut and skin health. Their use is well established in food, nutrition, and increasingly in topical and cosmetic formulations.

Other names
Prebiotic carbohydrateOSC (Oligosaccharide, nonspecific)Prebiotic fiberFunctional oligosaccharideDietary oligosaccharideFructo-oligosaccharide (FOS)Galacto-oligosaccharide (GOS)Human milk oligosaccharide (HMO)Xylo-oligosaccharide (XOS)Isomalto-oligosaccharide (IMO)
02

Mechanism of action

Serve as selective substrates for fermentation by beneficial gut bacteria (not digested by human enzymes); Promote the growth of Bifidobacterium, Lactobacillus (and sometimes other commensals), leading to increased SCFA production, lowered colonic pH, inhibition of pathogenic bacteria, and modulation of immune responses; In skin and systemic settings: modulation of microbiota and immune system, antioxidant effects, improvement of barrier integrity

03

Biological functions

Modulation of host microbiota (promote beneficial bacteria, especially Bifidobacterium and Lactobacillus)SCFA (short-chain fatty acid) production via fermentation by gut bacteriaRegulation of immune function and reduction of inflammationEnhancement of gut barrier integrityPotential antioxidant activitiesImprovement of skin health via microbiota modulation
04

Disease associations

Inflammation (anti-inflammatory effects through gut microbiota modulation and SCFA production)Allergy (modulation of immune responses, potential reduction of allergy risk)Infection (enhanced barrier function; indirect effects on pathogens through competition)Other (support for atopic dermatitis, metabolic syndrome, some skin conditions, digestive disorders)
05

Safety considerations

Generally regarded as safe (GRAS) in food, butGastrointestinal discomfort, bloating, or flatulence from excessive consumptionRarely, in specific populations (FODMAP sensitivity, SIBO), may worsen symptoms
06

Interacting drugs

None (Prebiotic oligosaccharides do not have traditional pharmacological drug–target interactions. They do not bind drugs in the manner of protein targets; they can, however, be co-administered with probiotics as synbiotics)
07

Biomarkers

Microbiota composition analysis (rise in Bifidobacterium or Lactobacillus counts)Short-chain fatty acid levels (e.g., butyrate or acetate in stool)Immune markers (e.g., Treg cell numbers, cytokine profiles)Epithelial barrier integrity parameters

Beyond the preview

Go deeper on Prebiotic oligosaccharide (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prebiotic oligosaccharide (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call